Evidence map›Paper›PMID 32758690›Full record

ReviewInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020

Marburg virus disease: A summary for clinicians.

Mark G Kortepeter, Kerry Dierberg, Erica S Shenoy, Theodore J Cieslak, Medical Countermeasures Working Group of the National Ebola Training and Education Center's (NETEC) Special Pathogens Research Network (SPRN)

Open access · goldAbstract readReview
In one paragraph

Review in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Nipah virus: a summary for clinicians.International journal of emergency medicine · 2025
    Review
  15. Refining early detection of Marburg Virus Disease (MVD) in Rwanda: Leveraging predictive symptom clusters to enhance case definitions.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Marburg Virus Disease: A Narrative Review.Health science reports · 2025
    Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Mark G KortepeterUniversity of Nebraska Medical Center, Omaha, NE, USA. Electronic address: Mark.kortepeter@gmail.com.
Kerry DierbergBellevue Hospital Center, New York, NY, USA.
Erica S ShenoyMassachusetts General Hospital, Boston, MA, USA.
Theodore J CieslakUniversity of Nebraska Medical Center, Omaha, NE, USA.
Medical Countermeasures Working Group of the National Ebola Training and Education Center's (NETEC) Special Pathogens Research Network (SPRN)
University of Nebraska Medical Center · USBellevue Hospital Center · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis article summarizes the countermeasures for Marburg virus disease, focusing on pathogenesis, clinical features and diagnostics. There is an emphasis on therapies and vaccines that have demonstrated, through their evaluation in nonhuman primates (NHPs) and/or in humans, potential for use in an emergency situation.

methodsA standardized literature review was conducted on vaccines and treatments for Marburg virus disease, with a focus on human and nonhuman primate data published in the last five years. More detail on the methods that were used is summarized in a companion methods paper.

resultsThe study identified six treatments and four vaccine platforms that have demonstrated, through their efficacy in NHPs, potential benefit for treating or preventing infection in humans.

conclusionSuccinct summaries of Marburg countermeasures are provided to give the busy clinician a head start in reviewing the literature if faced with a patient with Marburg virus disease. Links to other authoritative sources of information are also provided.

Indexed as

AnimalsHumansMarburgvirusMarburg Virus DiseaseViral VaccinesViral VaccinesAntiviral countermeasureAntiviral therapyEbola virusFilovirusMarburg virusTreatmentVaccine

Identifiers

PMID32758690
PMCPMC7397931
OpenAlexW3047616385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.